Although anti-PD-L1/PD-1 immunotherapy has shown marked clinical effect in a broad range of cancer, a subset of patients respond to monotherapy, and tumor mutation burden have been identified as potential predictive marker for responders. The gene discussed is PDCD1; the disease is neoplasm.